I.
Introduction Rheumatoid arthritis (RA) is a chronic , systemic , inflammatory disorder that may affect many tissues and organs ,once a diagnosis is made , the main treatment goals are to control disease activity and slow the rate of joint damage ,in addition to minimizing pain,stiffnes,inflammation and complications, pharmacologic therapies that are used include : a-nonbiologic and biologic (DMARDs ).
b-adjunctive agents such as (Corticosteroids,NSAIDs , Analgesics).
( 1 ) From biologic treatment : -TNFα inhibitors: Tumor necrosis factor alpha (TNF α) is a pro-inflammatory cytokine produce by macrophages and lymphocytes.) 2 ) -Non -TNFα agents:Rituximab(B-Cell Depletion):B-cells are an importantinflamma-tory cell withmultiple functions in the immune response , and these are effected on : -IL-17 : Interleukin -17 has been implicated in the pathogenesis of a wide range of diseases, IL-17 response can be modulated by multiple cytokines . A combination treatment of Ifliximab , an anti -TNF-α antibody, and methotrexate, an antimetabolite , is shown to significantly reduce disease along with decrease in the frequency of Th-17 cells and the levels of IL-17 in RA patients without significant adverse effects , clinical trials aimed at inhibiting IL -17 response show that such anagent holds promise as an efficacious treatment for arthritis . ( 3 ) II. Subjects and Methods:-70 patients were enrolled in this study their age range from 20 -68 years. The patients were divided into three groups : Group1consist of 20 RA patients received DMARDs(disease modifyinganti rheumatic drugs ) , while group 2 and group 3 consists 50 patients received biological treatment : one group of them include25 patients received Etanercept ( anti -TNF α ) and the other groupinclude 25 patients received Rituximab ( anti -CD20 ) ,with 20 healthy volunteers as control whose their ages and gender were matched with patients group. The assay employs the quantitative sandwich enzyme immunoassay technique . Antibody specific for IL-17 has been pre-coated onto a miceoplate . Standards and samples are pipetted into the wells and any IL-17 present is bound by the immobilized antibody . After removing any unbound substances , a biotin-conjugated antibody specific for IL-17 is added to the wells . After washing , avidinconjugated Horseradish Peroxidase ( HRP ) is added to the wells . Following a wash to remove any unbound avidin-enzyme reagent , a substrate solution is added to the wells and color develops in proportion to the amount of IL-17 bound in the initial step . The color development is stopped
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III. Results
The results in present study showed that there is significant elevation in the median serum level of IL-17 in healty control than those of RA patients table 1 and figure 1. Comparison among RA groups revealed that group 1patients has higher levels of IL-17 than those of patients in group 2 (5.268±0.69 and 3.811 ± 0.694 respectively),and group 2 patients has higher levels ofIL-17 than those of patients in group 3 , there is statistical significant difference between them every one to other P=0.01 , table 2 and figure2. 
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An anticipated median serum level of IL-17were also decreasesignificantly in patients treated with Rituximab group 3 ( 2.28 ) than those of group 2 Etanercept (anti-TNFα) treated group patients (3.3)table 3 and figure 3. 
IV. Discussion
Current findings suggest that the management strategy of RA disease status should be improved with an alternative regimen ,inversely ,patients treated with biologic therapy ( Etanercept and Rituximab ) showed lower serum IL-17 level when compared with healthy control or when compared with patients recivedDMARDs,P<0.01,P <0.01 respectively . These results are inagreement with results reported by other studies , who stated thatRituximab reduced the local Th 17 response in RA patients , and thedecreased Th17 response was associated with strongly reduced IL-17 as well as reduced inflammation and better clinical outcome.
These results with current findingssupport that the IL-17is highlyexpressed in the inflammatory joints and drives disease activity , implicating it as a key cytokine and potential therapeutic target . These studies have shown that IL-17not only drives theproinflammatory response but also enhances the effect of TNF-αpromoting increased destruction in the RA joint ( 4 ; 5 ). The current study support that IL-17 implicated in pathology ofRA disease especially in active disease rather than remission or milder cases . This statement argued by several researches ( 6 ; 7 ; 8 ) Implication of IL-17 in the RA disease may be explain withdifferent mechanisms , either by promoting matrix turnover andcartilage destruction ,especially in the presence of other cytokines ,mimicking the joint environment ( 4 ) mimicking the joint environment ( 9 ) , or stimulate osteoclast increasing orcompletetion of proinflammatory network IL-1 and TNF-α inducing joint inflammation and pathology by inducingsynivium matrix destruction ( 10 )and inducing cartilage breakdown ( 11 ) 
